Skip to content

Study · Animal study (in vivo) · rat · 1999

3 results

Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats.

Sikiric P, Jadrijevic S, Seiwerth S, Sosa T, Deskovic S, Perovic D, Aralica G, Grabarevic Z, Rucman R, Petek M, Jagic V, Turkovic B and 13 more

Show all authors

Ziger T, Rotkvic I, Mise S, Zoricic I, Sebecic B, Patrlj L, Kocman B, Sarlija M, Mikus D, Separovic J, Hanzevacki M, Gjurasin M, Miklic P

Journal of physiology, Paris1 Dec 1999Cited by 17 (Europe PMC)

PMID10672991 (opens in a new tab)DOI10.1016/s0928-4257(99)00124-2 (opens in a new tab)PepBankPUB-10672991
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In gastrectomized rats with oesophagojejunal anastomosis, BPC‑157 markedly attenuated reflux oesophagitis over a prolonged period.

    In plain wordsIn rats, BPC‑157 in drinking water strongly reduced reflux damage to the oesophagus over weeks.

    Peptide
    BPC-157
    Outcome
    DecreaseReflux oesophagitis severity
    Study

    ratn: not reported in source

    total gastrectomy with oesophagojejunal anastomosis (reflux oesophagitis)
    Comparator
    Water control
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    125 mg or 125 ng/kg daily · oral (drinking water) · 7, 14 or 28 daysAs given in this study (rat).

    Source sentences

    Summary
    pentadecapeptide BPC 157 markedly attenuated termino-lateral oesophagojejunal anastomosis-reflux oesophagitis also over a quite prolonged period.
    2 context sentences
    Summary · context
    Based on previous experiments, the doses of agents were daily calculated per kg b.w. as follows: BPC 157 125 mg or 125 ng, cholestyramine 2.5 mg, ranitidine 125 mg, sucralfate 725 mg, whereas controls received 72.5 mL x kg(-1) water.
    Summary · context
    The animals were euthanized 7, 14 or 28 d after surgery, when oesophagitis was blindly assessed both macroscopically (percentage of ulcerations areas) and microscopically (percentage of areas of ulcers, regeneration and hyperplasia; number of inflammatory cells - polymorphonuclear and mononuclear).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In gastrectomized rats with reflux oesophagitis, BPC‑157-treated groups had fewer polymorphonuclear cells than controls in all assessed periods.

    In plain wordsIn rats, BPC‑157 led to fewer inflammatory cells (polymorphonuclears) in the oesophagus than in controls.

    Peptide
    BPC-157
    Outcome
    DecreasePolymorphonuclear cell count in oesophagitis
    Study

    ratn: not reported in source

    total gastrectomy with oesophagojejunal anastomosis (reflux oesophagitis)
    Comparator
    Water control
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    125 mg or 125 ng/kg daily · oral (drinking water) · 7, 14 or 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Compared with control values, BPC 157-treated groups consistently presented less polymorphonuclears
    1 context sentence
    Summary · context
    The animals were euthanized 7, 14 or 28 d after surgery, when oesophagitis was blindly assessed both macroscopically (percentage of ulcerations areas) and microscopically (percentage of areas of ulcers, regeneration and hyperplasia; number of inflammatory cells - polymorphonuclear and mononuclear).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In gastrectomized rats with reflux oesophagitis, BPC‑157-treated groups had fewer mononuclear cells than controls in all assessed periods.

    In plain wordsIn rats, BPC‑157 led to fewer inflammatory cells (mononuclears) in the oesophagus than in controls.

    Peptide
    BPC-157
    Outcome
    DecreaseMononuclear cell count in oesophagitis
    Study

    ratn: not reported in source

    total gastrectomy with oesophagojejunal anastomosis (reflux oesophagitis)
    Comparator
    Water control
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    125 mg or 125 ng/kg daily · oral (drinking water) · 7, 14 or 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Compared with control values, BPC 157-treated groups consistently presented less polymorphonuclears and less mononuclears in all assessed periods
    1 context sentence
    Summary · context
    The animals were euthanized 7, 14 or 28 d after surgery, when oesophagitis was blindly assessed both macroscopically (percentage of ulcerations areas) and microscopically (percentage of areas of ulcers, regeneration and hyperplasia; number of inflammatory cells - polymorphonuclear and mononuclear).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.